维普期刊资源整合服务平台（V6.5）

53篇 您的检索式：作者名="Baila"

选中清除导出查看参考文献查看引证文献引用追踪共3页首页上一页第1页下一页末页 /3 跳转

	题名	作者	年代	出处	被引量
1	Dual behavior of HCV Core gene in regulation of apoptosis is important in progression of HCC显示文摘	Shah Jahan Usman A. Ashfaq Saba Khaliq Baila Samreen Nadeem Afzal	2012	Infection Genetics and Evolution2012，，2：	4
2	Impact of selected process parameters on crust flaking of frozen partly baked bread 显示文摘	Le BailA Monteau J Y Margerie F	2005	Journal of Food Engineering2005，69，：	1
3	Low dose decitabine versus best supportive care in elderly patients with intermediate or high risk MDS not eligible for intensive chemotherapy:final results of the randomized phase Ⅲ study (06011) of the EORTC leukemia and German MDS study groups显示文摘	Wijermans P Suciu S Baila L	2008	Blood2008，112，：	1
4	The role of the gypsum in bonesubstitution: molecular biological approach?based on own researchresults显示文摘	Lazary A BaIla B Kosa Ko	2007	Orv Heti2007，148，51：	1
5	Low dosedecitabine versus best supportive care in elderly pa-tients with intermediate or high-risk MDS not eligiblefor intensive chemotherapy:Final results of the ran-domized phaseⅢstudy(06011)of the EORTC leuke-mia and German MDS study groups显示文摘	WIJERMANS P SUCIU S BAILA L	2008	Blood2008，112，：	1
6	Low-dose decitabine versus best supportive care in elderly patients with intermediate or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase Ⅲ study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group显示文摘	Lubbert M Suciu S Baila L	2011	J Clin Oncol2011，29，15：	1
7	Low-dose decitabine ver- sus best supportive care in elderly patients with intermediate or high-risk myelodysplastic syndrome (MDS) ineligible for in- tensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treat- ment of Cancer Leukemia Group and the German MDS Study Group显示文摘	Ltibbert M Suciu S Baila L	2011	J Clin Oncol2011，29，15：	1
8	Interaction of the hepatitis C virus (HCV) core with cellular genes in the development of HCV-induced steatosis显示文摘	Mahwish Khan Shah Jahan Saba Khaliq Bushra Ijaz Waqar Ahmad Baila Samreen Sajida Hassan	2010	Archives of Virology2010，，11：	1
9	Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase IlI study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group显示文摘	LUBBERT M SUCIU S BAILA L	2011	J C/in Oncol2011，29，15：	1
10	Dual behavior of HCV Core gene in regulation of apoptosis is important in progression of HCC显示文摘	Shah Jahan Usman A. Ashfaq Saba Khaliq Baila Samreen Nadeem Afzal	2012	Infection Genetics and Evolution2012，，2：	1
11	Low-dose decitabine versus best supportive care in elderly pa- tients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemothera- py:final results of the randomized phase III study of the European Organisation for Research and Treat- ment of Cancer Leukemia Group and the German MDS Study Group显示文摘	LOBBERT M SUCIU S BAILA L	2011	J Clin Oncol2011，29，：	1
12	Low Dose Decitabine Versus Best Supportive Care in Eld III Study (0erly Patients with Intermediate or High Risk MDS Not Eligible for Intensive Chemotherapy: Final Results of the Randomized Phase6011) of the EORTC Leukemia and Ger- man MDS Study Groups显示文摘	WlJERMANS P SUCIU S BAILA L	2008	Blood (ASH Annual Meeting Abstracts)2008，112，：	1
13	Low-dose decitabine versus best supportive care in elderly patients with intermediate-or high-risk myelodysplastic syndrome(MDS)ineligible for intensive chemotherapy:final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group显示文摘	LBBERT M SUCIU S BAILA L	2011	J Clin Oncol2011，29，：	1
14	Low-dose decitabine versus best supportive care in elderly patients with intermediate-or high-riskmyelodysplastic syndrome(MDS)ineligible for intensive chemotherapy:final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDSStudy Group显示文摘	Lübbert M Suciu S Baila L	2011	J Clin Oncol2011，29，15：	1
15	Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy:final results of the randomized phase m study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group 显示文摘	Ltibbert M Suciu S Baila L	2011	J Clin Oneo12011，29，15：	1
16	Low-dose decitabine versus best supportive care in elderly patients with intermediate-or high-risk myelodysplastie syndrome (MDS) ineligible for intensive ehemotherapy: final results of the randomized phase study of the european organisation for research and treatment of cancer leukemia group and the german MDS study group显示文摘	Liibbert M Suciu S Baila L el: al	2011	J Clin Oncol2011，29，15：	1
17	Low-dose decitabine versus best supportive care in elderly patients with intermediate-or high-risk myelodysplastic syndrome(MDS) ineligible for intensive chemotherapy:final results of the randomized phase Ⅲ study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the GermanMDS Study Group显示文摘	Lübbert M Suciu S Baila L	2011	J Clin Oncol2011，29，15：	1
18	Low-dose decitabine versus best supportive care in elderly patients with intermediate or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy:final results of the randomized phase III study of the European Organisation for Resear显示文摘	Lubbert M Suciu S Baila L		0，，15：	1
19	Low-dose decitabine versus best supportive care in elderly patients with Inter- mediate-or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase 11 study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group显示文摘	Ltibbert M Suciu S Baila L	2011	J Clin Oncol2011，29，15：	1
20	GMP-compliant isolation and expansion of bone marrow-derived MSCs in the closed,automated device Quantum Cell Expansion system显示文摘	Rojewski MT Fekete N Baila S	2012	Cell Transplant2012，，：	1

返回顶部每页显示：

共3页首页上一页第1页下一页末页 /3 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示